Sometimes, it’s necessary for a company to take a step back before it can take two steps forward. Just ask the leaders of the Uniphar Group, a leading provider within the pharmaceutical and health care sector in Ireland.
In 2011, the combination of loan debt and high overhead was making it difficult for Uniphar to capitalize on growth opportunities. Just three years later, against a challenging economic backdrop, its annual revenues increased almost 60 percent, earnings were up 75 percent, and debt decreased by about a third. It also completed a major acquisition and initiated an SAP implementation across the organization.
Along the way, Deloitte Ireland has played a key role in Uniphar’s resurgence.
“Our corporate finance team was hired in 2011 by two Irish banks to complete an extensive review of Uniphar’s financial health and assist with negotiating a restructuring of the company’s existing loans to harness growth opportunities in the market,” explains David Carson, Deloitte Ireland’s lead client service partner for Uniphar. “By 2013, those banks were willing to fund Uniphar’s US$54.3 million acquisition of pharmaceutical wholesaler Cahill May Roberts (CMR). That speaks volumes about the progress Uniphar made and the trust the banks had in its management team.” Deloitte Ireland corporate finance provided due diligence services on the acquisition.
Shortly after the CMR deal closed, Uniphar conducted a series of road shows for customers and existing shareholders—the community pharmacists who own Uniphar—seeking US$22.5 million in equity investments to strengthen its balance sheet and improve its net debt-to-equity ratio. The share issue was heavily oversubscribed, leading the company’s board of directors to expand the maximum threshold to US$28.1 million. The board had to refuse about US$9 million in funding from outside investors.